Mineralys CFO trades on 11/11/2025; post-trade 19,396 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics (MLYS) Form 4: CFO and Secretary reported option exercises and share sales on 11/11/2025. He exercised options for 20,547 shares at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44. Same day, he executed multiple open-market sales, including 38,900 shares at a weighted-average price of $45.9277 and 32,718 at $46.8848, with other sales reported at weighted-average prices between $41.6522 and $46.8848.
Following the transactions, he directly beneficially owned 19,396 shares. The filing also notes that since his last ownership report, 83,598 shares were transferred to an ex-spouse pursuant to a domestic relations order.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 119,524 shares ($5,363,716)
Net Sell
17 txns
Insider
Levy Adam Scott
Role
CFO and Secretary
Sold
119,524 shs ($5.36M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 20,547 | $0.00 | -- |
| Exercise | Stock Option | 34,414 | $0.00 | -- |
| Exercise | Stock Option | 44,079 | $0.00 | -- |
| Exercise | Stock Option | 6,613 | $0.00 | -- |
| Exercise | Common Stock | 20,547 | $10.20 | $210K |
| Exercise | Common Stock | 34,414 | $16.00 | $551K |
| Exercise | Common Stock | 44,079 | $14.25 | $628K |
| Exercise | Common Stock | 6,613 | $15.44 | $102K |
| Sale | Common Stock | 1,015 | $42.00 | $43K |
| Sale | Common Stock | 11,295 | $41.8709 | $473K |
| Sale | Common Stock | 1,561 | $42.6794 | $67K |
| Sale | Common Stock | 12,952 | $41.6522 | $539K |
| Sale | Common Stock | 8,485 | $42.3404 | $359K |
| Sale | Common Stock | 4,142 | $43.5015 | $180K |
| Sale | Common Stock | 8,456 | $45.1805 | $382K |
| Sale | Common Stock | 38,900 | $45.9277 | $1.79M |
| Sale | Common Stock | 32,718 | $46.8848 | $1.53M |
Holdings After Transaction:
Stock Option — 135,674 shares (Direct);
Common Stock — 53,814 shares (Direct)
Footnotes (1)
- Since the date of the Reporting Person's last ownership report, 83,598 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.4500 to $42.2800. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.5100 to $42.9150. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0550 to $42.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1000 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4700 to $45.4600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4800 to $46.4725. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4900 to $47.3600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Since the date of the Reporting Person's last ownership report, 13,779 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter. Since the date of the Reporting Person's last ownership report, 42,442 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Since the date of the Reporting Person's last ownership report, 64,329 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Since the date of the Reporting Person's last ownership report, 8,499 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
FAQ
What did MLYS’s CFO report on the latest Form 4?
He exercised stock options and sold shares on 11/11/2025, then directly beneficially owned 19,396 shares.
How many options did the MLYS CFO exercise and at what prices?
He exercised 20,547 at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44.
What is the officer’s relationship to Mineralys Therapeutics (MLYS)?
He is the company’s CFO and Secretary.